Cosmo and Hyphens Announce Signing of License and Supply Agreements for Winlevi® in Southeast Asia
Cosmo Pharmaceuticals N.V. (“Cosmo”) and Hyphens Pharma International Limited (SGX: 1J5) (“Hyphens”) today announced the signing of License and Supply Agreements for Winlevi® (clascoterone) cream 1% in Southeast Asia.
Heidelberg Pharma Signs Research and Exclusive Option Agreement with Binghamton University on Immunostimulatory Technology Platform
Heidelberg Pharma AG today announced that it has entered into a research and exclusive option agreement with Binghamton University, State University of New York, Binghamton, NY, USA, related to a novel and proprietary immunostimulatory technology platform.
Encouraging Clinical Data from Two Antibody Drug Conjugates Based on Heidelberg Pharma’s ATAC Technology Presented at the ASH Annual Meeting 2022
Heidelberg Pharma AG (FSE: HPHA) today announced that initial clinical data from two Antibody Drug Conjugates (ADCs) based on the Company’s proprietary ATAC technology was presented at the ASH Annual Meeting 2022. Heidelberg Pharma showed preliminary safety data from the clinical trial with its candidate HDP-101 and partner Magenta Therapeutics, Cambridge, MA, USA, (Magenta) (NASDAQ: MGTA) presented in an oral session preliminary positive safety and initial efficacy data from its clinical trial with the ATAC candidate MGTA-117.
CureVac Members of Management Sell Shares to Cover Tax Obligations from Long Term Incentive Program
CureVac N.V., a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced that Chief Executive Officer Franz-Werner Haas, Chief Financial Officer Pierre Kemula and Interim Chief Development Officer Ulrike Gnad-Vogt sold an aggregate of 103,775 CureVac common shares. The sales were made solely to cover tax and social security obligations from a legacy Virtual Stock Option Plan (Prior VSOP), which granted virtual options to key members of management. The tax obligations arose as a result of option exercises pursuant to the terms of the Prior VSOP.
Except for tax obligations, all three members of the management team do not plan to sell additional shares in the foreseeable future.
Apogenix Enrolls First Patients in Pivotal Phase III Trial for the Treatment of Hospitalized COVID-19 Patients with Asunercept
Apogenix, a biopharmaceutical company developing next generation immunotherapeutics, announced today that the first patients have been enrolled in a pivotal phase III trial to investigate the efficacy and safety of asunercept on top of standard of care (SoC) for the treatment of hospitalized patients with moderate to severe COVID-19 disease (ASUCOV; NCT05639192). The multicenter, double-blind, placebo-controlled trial aims to enroll more than 600 hospitalized patients requiring oxygen in nine different countries.
Cosmo announces successful Phase III clinical trial of Lumeblue™ in China
Cosmo Pharmaceuticals N.V. (“Cosmo”) today announced the successful phase III clinical trial of Lumeblue™ in China, sponsored by its partner China Medical System Holdings Limited (CMS) (867.HK).
AC Immune’s Alzheimer’s Disease Vaccine-candidate ACI-35.030 Selected for Further Development
AC Immune SA, a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that based on the Phase 1b/2a interim data, ACI-35.030, a potential first-in-class anti-phosphorylated-Tau (pTau) vaccine candidate, has been selected for further development. The ACI-35.030 anti-pTau vaccine candidate is being developed in collaboration with Janssen Pharmaceuticals, Inc. (Janssen), part of the Janssen Pharmaceutical Companies of Johnson & Johnson.
AC Immune to Present Progress of Alzheimer’s Disease Programs targeting Abeta and Tau at the 15th CTAD Conference
AC Immune SA, a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced the upcoming presentations of its vaccine technology SupraAntigen®, and of its anti-Tau and anti-Abeta investigational candidates, at the 15th Clinical Trials on Alzheimer’s Disease (CTAD) conference in San Francisco, California (United States) and online, on November 29 – December 2, 2022.
Immatics Announces Third Quarter 2022 Financial Results and Business Update
Immatics N.V. (“Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today provided a business update and reported financial results for the quarter ended September 30, 2022.
CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2022 and Provides Business Update
CureVac N.V., a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced financial results for the third quarter and first nine months of 2022 and provided a business update.
dievini Hopp BioTech holding GmbH & Co. KG | Impressum | Datenschutz